FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308182085> ?p ?o ?g. }

• W4308182085 endingPage "2201794" @default.
• W4308182085 startingPage "2201794" @default.
• W4308182085 abstract "Background GLPG1205 is a selective functional antagonist of G-protein-coupled receptor 84, which plays an important role in fibrotic processes. This study assessed the efficacy, safety and tolerability of GLPG1205 for treatment of idiopathic pulmonary fibrosis (IPF). Methods PINTA ( ClinicalTrials.gov : NCT03725852 ) was a phase 2, randomised, double-blind, placebo-controlled, proof-of-concept trial. Patients with IPF were randomised 2:1 to once-daily oral GLPG1205 100 mg or placebo for 26 weeks and stratified to receive GLPG1205 alone or with local standard of care (nintedanib or pirfenidone). The primary end-point was change from baseline in forced vital capacity (FVC); other end-points were safety and tolerability, and lung volumes measured by imaging (high-resolution computed tomography). The study was not powered for statistical significance. Results In total, 68 patients received study medication. Least squares mean change from baseline in FVC at week 26 was −33.68 (95% CI −112.0–44.68) mL with GLPG1205 and −76.00 (95% CI −170.7–18.71) mL with placebo (least squares mean difference 42.33 (95% CI −81.84–166.5) mL; p=0.50). Lung volumes by imaging declined −58.30 versus −262.72 mL (whole lung) and −33.68 versus −135.48 mL (lower lobes) with GLPG1205 versus placebo, respectively. Treatment with GLPG1205 versus placebo resulted in higher proportions of serious and severe treatment-emergent adverse events and treatment-emergent discontinuations, most apparent with nintedanib. Conclusions Treatment with GLPG1205 did not result in a significant difference in FVC decline versus placebo. GLPG1205 demonstrated a poorer safety and tolerability profile than placebo." @default.
• W4308182085 created "2022-11-09" @default.
• W4308182085 creator A5002896875 @default.
• W4308182085 creator A5014703126 @default.
• W4308182085 creator A5022174775 @default.
• W4308182085 creator A5026245835 @default.
• W4308182085 creator A5030002201 @default.
• W4308182085 creator A5041881590 @default.
• W4308182085 creator A5051127850 @default.
• W4308182085 creator A5052194667 @default.
• W4308182085 creator A5057747316 @default.
• W4308182085 creator A5068330798 @default.
• W4308182085 creator A5073899811 @default.
• W4308182085 creator A5084223886 @default.
• W4308182085 creator A5090203143 @default.
• W4308182085 date "2022-11-03" @default.
• W4308182085 modified "2023-10-11" @default.
• W4308182085 title "GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial" @default.
• W4308182085 cites W2011826235 @default.
• W4308182085 cites W2098530232 @default.
• W4308182085 cites W2138871107 @default.
• W4308182085 cites W2168666423 @default.
• W4308182085 cites W2753035500 @default.
• W4308182085 cites W2785444851 @default.
• W4308182085 cites W2797176335 @default.
• W4308182085 cites W2804909402 @default.
• W4308182085 cites W2889197569 @default.
• W4308182085 cites W2890575335 @default.
• W4308182085 cites W2899774017 @default.
• W4308182085 cites W2906656165 @default.
• W4308182085 cites W3084224372 @default.
• W4308182085 cites W4206820024 @default.
• W4308182085 cites W4237585890 @default.
• W4308182085 cites W4280599153 @default.
• W4308182085 doi "https://doi.org/10.1183/13993003.01794-2022" @default.
• W4308182085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36328358" @default.
• W4308182085 hasPublicationYear "2022" @default.
• W4308182085 type Work @default.
• W4308182085 citedByCount "8" @default.
• W4308182085 countsByYear W43081820852023 @default.
• W4308182085 crossrefType "journal-article" @default.
• W4308182085 hasAuthorship W4308182085A5002896875 @default.
• W4308182085 hasAuthorship W4308182085A5014703126 @default.
• W4308182085 hasAuthorship W4308182085A5022174775 @default.
• W4308182085 hasAuthorship W4308182085A5026245835 @default.
• W4308182085 hasAuthorship W4308182085A5030002201 @default.
• W4308182085 hasAuthorship W4308182085A5041881590 @default.
• W4308182085 hasAuthorship W4308182085A5051127850 @default.
• W4308182085 hasAuthorship W4308182085A5052194667 @default.
• W4308182085 hasAuthorship W4308182085A5057747316 @default.
• W4308182085 hasAuthorship W4308182085A5068330798 @default.
• W4308182085 hasAuthorship W4308182085A5073899811 @default.
• W4308182085 hasAuthorship W4308182085A5084223886 @default.
• W4308182085 hasAuthorship W4308182085A5090203143 @default.
• W4308182085 hasBestOaLocation W43081820851 @default.
• W4308182085 hasConcept C126322002 @default.
• W4308182085 hasConcept C141071460 @default.
• W4308182085 hasConcept C142724271 @default.
• W4308182085 hasConcept C165637977 @default.
• W4308182085 hasConcept C168563851 @default.
• W4308182085 hasConcept C197934379 @default.
• W4308182085 hasConcept C203092338 @default.
• W4308182085 hasConcept C204787440 @default.
• W4308182085 hasConcept C27081682 @default.
• W4308182085 hasConcept C2777714996 @default.
• W4308182085 hasConcept C2778341716 @default.
• W4308182085 hasConcept C2778375690 @default.
• W4308182085 hasConcept C2780171596 @default.
• W4308182085 hasConcept C3018587741 @default.
• W4308182085 hasConcept C55520419 @default.
• W4308182085 hasConcept C71924100 @default.
• W4308182085 hasConcept C90924648 @default.
• W4308182085 hasConceptScore W4308182085C126322002 @default.
• W4308182085 hasConceptScore W4308182085C141071460 @default.
• W4308182085 hasConceptScore W4308182085C142724271 @default.
• W4308182085 hasConceptScore W4308182085C165637977 @default.
• W4308182085 hasConceptScore W4308182085C168563851 @default.
• W4308182085 hasConceptScore W4308182085C197934379 @default.
• W4308182085 hasConceptScore W4308182085C203092338 @default.
• W4308182085 hasConceptScore W4308182085C204787440 @default.
• W4308182085 hasConceptScore W4308182085C27081682 @default.
• W4308182085 hasConceptScore W4308182085C2777714996 @default.
• W4308182085 hasConceptScore W4308182085C2778341716 @default.
• W4308182085 hasConceptScore W4308182085C2778375690 @default.
• W4308182085 hasConceptScore W4308182085C2780171596 @default.
• W4308182085 hasConceptScore W4308182085C3018587741 @default.
• W4308182085 hasConceptScore W4308182085C55520419 @default.
• W4308182085 hasConceptScore W4308182085C71924100 @default.
• W4308182085 hasConceptScore W4308182085C90924648 @default.
• W4308182085 hasFunder F4320319293 @default.
• W4308182085 hasIssue "3" @default.
• W4308182085 hasLocation W43081820851 @default.
• W4308182085 hasLocation W43081820852 @default.
• W4308182085 hasLocation W43081820853 @default.
• W4308182085 hasOpenAccess W4308182085 @default.
• W4308182085 hasPrimaryLocation W43081820851 @default.
• W4308182085 hasRelatedWork W2119639538 @default.
• W4308182085 hasRelatedWork W2315538569 @default.

• next